Skip to content

Treatment of Hyperpyrexia and in the Pediatric Emergency Department (FEVER_ED)

Optimization of the Treatment of Hyperpyrexia and Associated Symptoms in the Pediatric Emergency Department (FEVER_ED)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06194383
Acronym
FEVER_ED
Enrollment
160
Registered
2024-01-08
Start date
2023-12-22
Completion date
2024-12-31
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fever

Brief summary

Fever represents the main cause of admission to the emergency room in older people pediatric. It occurs in the presence of a wide range of pathologies, from infectious forms (the most common, viral or bacterial) up to more complex and/or systemic forms (such as inflammatory or neoplastic ones). The drugs currently indicated for the management of fever in children are: paracetamol and ibuprofen. There are no recent studies conducted in pediatric population, who have demonstrated the greater effectiveness of therapy with paracetamol or ibuprofen, The objective of our study is, therefore, to identify which therapy is most appropriate for controlling body temperature e of associated symptoms in pediatric patients arriving in the emergency room with fever.

Interventions

None listed

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Months to 20 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric patients (aged between 6 months 0 and 20 years) * fever (T > 38°C) with/without associated symptoms, treated with standard antipyretic drugs orally (paracetamol, ibuprofen or paracetamol/ibuprofen combination) * who have expressed their consent to participate in the study.

Exclusion criteria

* age <6 months or >20 years; * patients who did not express consent to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Response to the treatment as evaluation of associated symptoms1 hourEvaluation of associated symptoms by pain scale

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026